European markets are expected to open slightly higher on Friday as investors look ahead to highly anticipated fiscal stimulus ...

Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

currently its main rival in the GLP-1 market with tirzepatide-based therapies Mounjaro and Zepbound. The two companies are in ...

Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.

In recent years, the sales of its blockbuster drugs, Mounjaro and Zepbound, which treat diabetes and obesity, respectively, ...

These drugs work similarly but differ in dosage and specific indications (uses). Research suggests that tirzepatide is more ...

As Novo Holdings hopes to close its $16.5 billion acquisition of CDMO Catalent by the end of the year, the deal is facing a fresh round of lawmaker scrutiny. | In a letter to the chair of the U.S.

The embattled diet brand said it is adding a compounded weight-loss drug in accordance with FDA rules and manufacturing ...

Eli Lilly intensifies its legal efforts against compounding pharmacies producing copycat versions of its weight-loss drugs, ...

If there’s a diet, Janet McCaskill says, she’s done it. “I’ve tried WeightWatchers. I’ve tried keto. I’ve gone to a ...

Men, baby boomers, and postgraduate-degree holders were among those most likely to say they wouldn’t choose medication over ...

Data readouts over the next six months could set expectations for how the highly lucrative market for weight loss therapies ...